Create mode – the default mode when you create a requisition and PunchOut to Bio-Rad. You can create and edit multiple shopping carts
Edit mode – allows you to edit or modify an existing requisition (prior to submitting). You will be able to modify only the cart that you have PunchedOut to, and won't have access to any other carts
Inspect mode – when you PunchOut to Bio-Rad from a previously created requisition but without initiating an Edit session, you will be in this mode. You cannot modify any Cart contents
Watch our latest video to see inside Bio-Rad’s custom antibody facility. Learn from antibody experts how your requirements for specialized custom antibodies can become a reality through the use of HuCAL technology.
Features
How specialized antibody reagents address the challenges of CAR-T cell therapy development
Dr Christian Frisch explains how we generate anti-idiotypic antibodies for bioanalytical assay development using the HuCAL recombinant antibody technology; recorded at the EBF 8th Open Meeting.
Hear how Bio-Rad’s recombinant anti-idiotypic antibodies, made using HuCAL technology, fulfill the high quality standards demanded for use in assays to support the clinical evaluation of monoclonal antibody drugs; recorded at the EBF 9th Open Meeting.
Michael Schwenkert describes how high sensitivity PK assays can be developed using specialized drug-target complex specific antibodies, avoiding the ELISA bridging format; recorded at the EBF 10th Open Meeting (Barcelona, November 2017).
Michael Schwenkert talks about challenges associated with the development of CAR-T cell therapies that can be addressed using anti-idiotypic antibodies, and explains how Bio-Rad generates custom antibodies for this application (Barcelona, November 2018).
Ulrich Mayer describes how bioanalytical scientists can address the challenges of robust, selective and sensitive PK and ADA assay development through the use of customized anti-biotherapeutic antibodies generated by Bio-Rad (Barcelona, November 2019).
Articles
Monitoring antibody immune responses against biotherapeutic drugs